Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC

Amivantamab, an antibody against MET and EGFR, plus lazertinib, an EGFR tyrosine kinase inhibitor, induced a response in 86% of previously untreated patients and led to a median progression-free survival of nearly 2 years.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology